Immunotherapy in Lung Cancer: Treatment After IO Cessation.

  • STATUS
    Recruiting
  • End date
    Jun 5, 2025
  • participants needed
    300
  • sponsor
    European Lung Cancer Working Party
Updated on 19 February 2024
cancer
lung cancer
non-melanoma skin cancer
chemoradiotherapy
carcinoma
immunomodulators
stage iv non-small cell lung cancer
stage iii non-small cell lung cancer
carcinoma in situ
salvage therapy
carcinoma of the cervix
adjuvant
melanoma
small cell lung cancer

Summary

Immunotherapy is now a standard of care for first-line and eventually salvage therapy in patients with stage IV NSCLC and as adjuvant after RT-CT for stage III NSCLC.

The aim of the study is determining the therapeutic landscape and the reason for immunotherapy cessation.

Description

Patients with stage IV or unresectable not irradiable stage III NSCLC will be registered at the time receiving immunotherapy alone or in combination with chemotherapy.

When IO is stopped, reason for cessation and further treatment will be recorded.

Secondary endpoints are survival after IO cessation, activity of first salvage therapy, disease-free survival after IO cessation in patients receiving no further treatment.

Patients will be centrally registered at the ELCWP headquarter (Institut Jules Bordet, Brussels, Belgium).

Details
Condition Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Immunotherapy
Age 18years - 100years
Treatment (chemo)immunotherapy
Clinical Study IdentifierNCT04465942
SponsorEuropean Lung Cancer Working Party
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Histological diagnosis of non-small cell lung cancer (NSCLC)
Stage IVA/IVB and unresectable and non irradiable stage III NSCLC nave of immunotherapy
Patients who receive immunotherapy (any type) monotherapy, combined immunotherapy or in combination with chemotherapy for first or second-line treatment
Availability for participating in the detailed follow-up of the protocol
Signed informed consent

Exclusion Criteria

Patients receiving adjuvant immunotherapy for stage I-III NSCLC are not eligible
Tumours for which TNM stage at time of study inclusion cannot be assessed
History of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or of the bladder or cured malignant tumor (more than 5-year disease free interval)
Any type of immunotherapy for previous cancer
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.